Malaria stage-specific vaccine candidates

Current Pharmaceutical Design

Volumn 13, Issue 19, 2007, Pages 1989-1999

  Kristoff, Jan ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antigenic variation; Innate immunity; Malaria; Premunition

Indexed keywords

ALUMINUM SALT; ANTIMALARIAL AGENT; APICAL MEMBRANE ANTIGEN 1; ARTEMISIN; CHLOROQUINE; CIRCUMSPOROZOITE PROTEIN; CYTOKINE; DNA VACCINE; ERYTHROCYTE BINDING ANTIGEN 175; GAMMA INTERFERON; ICC 1132; LIVE VACCINE; MALARIA VACCINE; MALARIVAX; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PHOSPHORYL LIPID A; PYRIMETHAMINE; RECOMBINANT VACCINE; SAPONIN DERIVATIVE; SESQUITERPENE LACTONE; SPOROZOITE AND LIVER STAGE ANTIGEN; SPOROZOITE SURFACE ANTIGEN; SPOROZOITE THREONINE AND ASPARAGINES RICH PROTEIN; SPOROZOITE VACCINE; SUBUNIT VACCINE; SULFADOXINE; THROMBOSPONDIN RELATED ADHESIVE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSMISSION BLOCKING VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASEXUAL REPRODUCTION; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENDEMIC DISEASE; HUMAN; IMMUNOLOGICAL MEMORY; LIFE CYCLE; MALARIA; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPOROZOITE; TREATMENT FAILURE; VECTOR CONTROL;

ANIMALS; HUMANS; MALARIA; MALARIA VACCINES;

EID: 34447274271     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039805     Document Type: Review

References (126)

1. Tongren JE, Zavala F, Roos DS, Riley EM. Malaria vaccines: if at first you don't succeed. Trends Parasitol 2004; 20(12): 604-10.
2. Struik SS, Riley EM. Does malaria suffer from lack of memory? Immunol Rev 2004; 201: 268-90.
3. Riley EM. Is T-cell priming required for initiation of pathology in malaria infections? Immunol Today 1999; 20(5): 228-33.
4. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ 1999; 77(8): 624-40.
5. Zambrano-Villa S, Rosales-Borjas D, Carrero JC, Ortiz-Ortiz L. How protozoan parasites evade the immune response. Trends Parasitol 2002; 18(6): 272-8.
6. Perkins DJ, Kremsner PG, Schmid D, Misukonis MA, Kelly MA, Weinberg JB. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria. Infect Immun 1999; 67(9): 4977-81.
7. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 2003; 3(6): 349-58.
8. Ridley RG. Malaria: to kill a parasite. Nature 2003; 424(6951): 887-9.
9. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424(6951): 957-61.
10. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol 2004; 4(3): 169-80.
11. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415(6872): 673-9.
12. Chong CR, Sullivan DJ, Jr. Inhibition of heme crystal growth by antimalarials and other compounds: implications for drug discovery. Biochem Pharmacol 2003; 66(11): 2201-12.
13. Ekvall H. Malaria and anemia. Curr Opin Hematol 2003; 10(2): 108-14.
14. Stoute JA, Odindo AO, Owuor BO, Mibei EK, Opollo MO, Waitumbi JN. Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. J Infect Dis 2003; 187(3): 522-5.
15. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003; 133(2): 145-52.
16. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 2003; 24(9): 491-9.
17. Kwiatkowski D, Bate CA, Scragg IG, Beattie P, Udalova I, Knight JC. The malarial fever response - pathogenesis, polymorphism and prospects for intervention. Ann Trop Med Parasitol 1997; 91(5): 533-42.
18. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis 2002; 185(7): 971-9.
19. Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey JO, Nkrumah FK, et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 1998; 351(9118): 1768-72.
20. Li C, Sanni LA, Omer F, Riley E, Langhorne J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun 2003; 71(9): 4850-6.
21. Omer FM, de Souza JB, Corran PH, Sultan AA, Riley EM. Activation of transforming growth factor beta by malaria parasite-derived metalloproteinases and a thrombospondin-like molecule. J Exp Med 2003; 198(12): 1817-27.
22. Omer FM, de Souza JB, Riley EM. Differential induction of TGF-beta regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J Immunol 2003; 171(10): 5430-6.
23. Tsutsui N, Kamiyama T. Transforming growth factor beta-induced failure of resistance to infection with blood-stage Plasmodium chabaudi in mice. Infect Immun 1999; 67(5): 2306-11.
24. Perkins DJ, Weinberg JB, Kremsner PG. Reduced interleukin-12 and transforming growth factor-β1 in severe childhood malaria: relationship of cytokine balance with disease severity. J Infect Dis 2000; 182: 988-92.
25. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998; 4(3): 358-60.
26. Struik SS, Omer FM, Artavanis-Tsakonas K, Riley EM. Uninfected erythrocytes inhibit Plasmodium falciparum-induced cellular immune responses in whole-blood assays. Blood 2004; 103(8): 3084-92.
27. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296(5566): 301-5.
28. Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, Drakely C, et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 1996; 8(6): 905-15.
29. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995; 63(11): 4382-8.
30. Good MF. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 2005; 21(1): 29-34.
31. Targett GA. Malaria vaccines 1985-2005: a full circle? Trends Parasitol 2005; 21(11): 499-503.
32. Carter R. Transmission blocking malaria vaccines. Vaccine 2001; 19(17-19): 2309-14.
33. Carter R, Graves PM, Quakyi IA, Good MF. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J Exp Med 1989; 169(1): 135-47.
34. Kaslow DC. Transmission-blocking immunity against malaria and other vector-borne diseases. Curr Opin Immunol 1993; 5(4): 557-65.
35. Kumar N, Ploton I, Koski G, Ann-Lobo C, Contreras C. Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Adv Exp Med Biol 1995; 383: 65-72.
36. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura, K, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005; 23(24): 3131-8.
37. Carter R, Mendis KN, Roberts D. Spatial targeting of interventions against malaria. Bull World Health Organ 2000; 78(12): 1401-11.
38. Malaria transmission blocking vaccines: an ideal public good. http://www.who.int/tdr/publications/pdf/malaria_tbv.pdf. Accessed April 26, 2006.
39. Coban C, Ishii KJ, Sullivan DJ, Kumar N. Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun 2002; 70(7): 3939-43.
40. Coban C, Philipp MT, Purcell JE, Keister DB, Okulate M, Martin DS, et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun 2004; 72(1): 253-9.
41. Templeton TJ, Kaslow DC. Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230. Mol Biochem Parasitol 1999; 101(1-2): 223-7.
42. Grotendorst CA, Kumar N, Carter R, Kaushal DC. A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies. Infect Immun 1984; 45(3): 775-7.
43. Tsuboi T, Kaslow DC, Cao YM, Shiwaku K, Torii M. Comparison of Plasmodium yoelii ookinete surface antigens with human and avian malaria parasite homologues reveals two highly conserved regions. Mol Biochem Parasitol 1997; 87(1): 107-11.
44. Miller LH, Howard RJ, Carter R, Good W, Nussenzweig V, Nussenzweig RS. Research toward malaria vaccines. Science 1986; 234(4782): 1349-56.
45. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185(8): 1155-64.
46. Tsuji M, Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 2003; 19(2): 88-93.
47. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266(3): 169-77.
48. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003; 206(Pt 21): 3803-8.
49. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967; 216(5111): 160-2.
50. Clyde DF, McCarthy VC, Miller RM, Homick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266(6): 398-403.
51. Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979; 57 (Suppl 1): 261-5.
52. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974; 68(3): 258-9.
53. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980; 207(4426): 71-3.
54. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987; 1(8545): 1277-81.
55. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987; 328(6127): 257-9.
56. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, Chesnut RW, et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997; 7(1): 97-112.
57. Doolan DL, Southwood S, Chesnut R, Appella E, Gomez E, Richards A, et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class 11 alleles. J Immunol 2000; 165(2): 1123-37.
58. Edelman R, Hoffman SL, Davis JR, Beier M, Sztein MB, Losonsky G, et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993; 168(4): 1066-70.
59. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau, GE, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993; 49(2): 166-73.
60. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991; 45(5): 539-47.
61. Hoffman SL, Franke ED, Druilhe MRHP. Attacking the infected hepatocyte. In: Hoffman SL Ed, Malaria vaccine development: A multi-immune response approach 1996; 35-75.
62. Hoffman SL, Miller LH. Perspectives on malaria vaccine development. In: Hoffman SL Ed, Malaria vaccine development: A multi-immune response approach 1996; 1-13.
63. Kryzch U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995; 155: 4072-7.
64. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 1991; 88(8): 3300-4.
65. Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Herrington D, et al. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol 1991; 3(10): 997-1003.
66. Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F, et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993; 151(1): 489-99.
67. Nardin EH. T cell responses in a sporozoite-immunized human volunteer and a chimpanzee. Immunol Lett 1990; 25(1-3): 43-7.
68. Nardin EH, Herrington DA, Davis J, Levine M, Stuber D, Takacs B, et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 1989; 246(4937): 1603-6.
69. Nardin EH, Nussenzweig RS, Altszuler R, Herrington D, Levine M, Murphy J, et al. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers. Bull World Health Organ 1990; 68 Suppl: 85-7.
70. Nussenzweig V, Nussenzweig RS. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989; 45: 283-334.
71. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364(9443): 1411-20.
72. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358(9297): 1927-34.
73. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183(4): 640-7.
74. Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004; 72(11): 6519-27.
75. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1.132 formulated in Seppic ISA 720. Vaccine 2005; 23(7): 857-64.
76. Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. J Exp Biol 2003; 206(Pt 21): 3771-9.
77. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95(13): 7648-53.
78. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004; 1(2): e33.
79. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191: 619-26.
80. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004; 363(9403): 150-6.
81. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9(6): 729-35.
82. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005; 433(7022): 164-7.
83. Rogers WO, Atuguba F, Oduro AR, Hodgson A, Koram KA. Clinical case definitions and malaria vaccine efficacy. J Infect Dis 2006; 193(3): 467-73.
84. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 1996; 64(8): 3310-7.
85. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185(6): 820-7.
86. Stanisic DI, Martin LB, Liu XQ, Jackson D, Cooper J, Good MF. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect Immun 2003; 71(10): 5700-13.
87. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400(6739): 73-7.
88. Arese P, Schwarzer E. Malarial pigment (haemozoin): a very active 'inert' substance. Ann Trop Med Parasitol 1997; 91(5): 501-16.
89. Schwarzer E, Alessio M, Ulliers D, Arese P. Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes. Infect Immun 1998; 66(4): 1601-6.
90. Schwarzer E, Turrini F, Giribaldi G, Cappadoro M, Arese P. Phagocytosis of P. falciparum malarial pigment hemozoin by human monocytes inactivates monocyte protein kinase C. Biochim Biophys Acta 1993; 1181(1): 51-4.
91. Schwarzer E, Turrini F, Ulliers D, Giribaldi G, Ginsburg H, Arese P. Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992; 176(4): 1033-41.
92. Zhang D, Pan W. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Infect Immun 2005; 73(10): 6530-6.
93. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, et al. A malaria vaccine that elicits in humans antibodies able to kill [i Plasmodium falciparum. PLoS Med 2005; 2(11): e344.
94. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73(12): 8017-26.
95. Crabb BS, Beeson JG. Promising functional readouts of immunity in a blood-stage malaria vaccine trial. PLoS Med 2005; 2(11): e380.
96. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999; 179(4): 980-8.
97. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360(9333): 610-7.
98. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006; 24(19): 4233-46.
99. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996; 173(3): 765-9.
100. Egan AF, Burghas P, Druihle P, Holder AA, Riley EM. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 1992; 21: 133-9.
101. 19, predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004; 72(3): 1557-67.
102. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007; 25(1): 176-84.
103. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ, et al. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem 2005; 280(48): 40169-76.
104. Black CG, Wang L, Wu T, Coppel RL. Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum. Mol Biochem Parasitol 2003; 127(1): 59-68.
105. Cowman AF, Crabb BS. The Plasmodium falciparum genome - a blueprint for erythrocyte invasion. Science 2002; 298(5591): 126-8.
106. Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, Nicholls SC, et al. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature 1985; 317(6034): 270-3.
107. McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK, et al. Molecular variation in a novel polymorphic antigen associated with [i Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 68(1): 53-67.
108. Pachebat JA, Ling IT, Grainger M, Trucco C, Howell S, Fernandez-Reyes D, et al. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol 2001; 117(1): 83-9.
109. Pearce JA, Mills K, Trigha T, Cowman AF, Anders RF. Characterisation of two novel proteins from the asexual stage of Plasmodium falciparum, H101 and H103. Mol Biochem Parasitol 2005; 139(2): 141-51.
110. Smythe JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85(14): 5195-9.
111. Topolska AE, Lidgett A, Truman D, Fujioka H, Coppel RL. Characterization of a membrane-associated rhoptry protein of Plasmodium falciparum. J Biol Chem 2004; 279(6): 4648-56.
112. Trucco C, Fernandez-Reyes D, Howell S, Stafford WH, Scott-Finnigan TJ, Grainger M, et al. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 2001; 112(1): 91-101.
113. Schofield L, Hackett F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med 1993; 177(1): 145-53.
114. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002; 418(6899): 785-9.
115. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357(9267): 1471-7.
116. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419(6906): 498-511.
117. Ben Mamoun C, Gluzman IY, Hott C, MacMillan SK, Amarakone AS, Anderson DL, et al. Co-ordinated programme of gene expression during asexual intraerythrocytic development of the human malaria parasite Plasmodium falciparum revealed by microarray analysis. Mol Microbiol 2001; 39(1): 26-36.
118. Bozdech Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, DeRisi JL. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol 2003; 4(2): R9.
119. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419(6906): 520-6.
120. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003; 301(5639): 1503-8.
121. Doolan DL, Aguiar JC, Weiss WR, Sette A, Felgner PL, Regis DP, et al. Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol 2003; 206(Pt 21): 3789-802.
122. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA 2003; 100(17): 9952-7.
123. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 2005; 365(9469): 1487-98.
124. Frantz S, Bauersachs J, Kelly RA. Innate immunity and the heart. Curr Pharm Des 2005; 11(10): 1279-90.
125. Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 2006; 12(32): 4203-13.
126. Seeber F, Aliverti A, Zanetti G. The plant-type ferredoxin-NADP+ reductase/ferredoxin redox system as a possible drug target against apicomplexan human parasites. Curr Pharm Des 2005; 11(24): 3159-72.